AssistMe raised a $7.5M round. Its 7 patent families sit in a crowded claim space, and that changes what its claims are worth
Three of AssistMe’s seven families are already granted, and the company is hiring 22 go-to-market roles out of 71 open positions. That combination is the interesting part. Granted patents are enforceable today, and the hiring pattern says commercialisation rather than research. When a company files early, gets grants, and then staffs sales, the filings stop being a research record and start being part of what is being sold.
The Round
AssistMe, founded in Germany in 2017, raised $7.5M from Conle Family Office, Next Big Thing and Sum Ventures. The company describes itself as digital pioneers for scientifically based and practice-proven smart assistance solutions to support care.
The Portfolio
Seven families since 2021. Three granted, four published and pending, and the first of those pending families could grant at any time. Filings are in DE, EP and WO, so German, European and international routes. Velocity was front-loaded: four families in 2021, one in 2023, two in 2024. Claims cluster in two areas, implants and eye treatment (A61F) and diagnosis and surgery (A61B). The most recent public filing titles point at the same technical ground: a circuit carrier for a clip for mounting on an absorbent article, a method of joining an absorbent article and a continuous strip, and a system and method for detecting an incontinence event in an absorbent article. That is sensing hardware and the method of attaching it, claimed from more than one angle.
The Company They Keep
The same CPC groups have drawn Philips with 943 families over the last five years, Samsung with 644, Procter & Gamble with 445, Zhejiang University with 419, Biosense Webster Israel with 388 and Medtronic with 330. This is a crowded space. In a crowded space, family count is a weak signal and claim scope is the real one. Seven families next to Philips at 943 is not a volume position, and it does not need to be. What matters is how narrowly or broadly the granted claims read on the specific combination of an absorbent article, a mounted clip and an event detection method. The citation record is early: AssistMe patents are cited by Tuli Raja, one citing publication. That is a thin trail, which is normal for a portfolio whose oldest families date to 2021.
The People
Nine inventors are named across seven families. Julio Brandl appears on three, Jonas Kathan on three, and Lemke Diego Carucci on two. So the invention work is spread across a real bench rather than resting on a single named founder-inventor, but two names carry most of it.
What to watch
Three things. First, grants. Four families are pending and the earliest of them is ripe, so the granted count could move from three to four without warning. Second, the publication window. The last public filing is dated 19 September 2024, which is 23 months before this round. Anything filed since then is still inside the 18-month blackout, so the public portfolio is very likely smaller than the actual one. Filings made around and after the round will surface later. Third, the hiring mix. Twenty-two go-to-market roles, 14 other, 12 software and AI, 11 bio and clinical, 8 ops and finance, and 4 hardware. Sample openings include customer support, customer success, and a freelance sales representative for digital health in France. Only four hardware roles against 22 in go-to-market suggests the device architecture is settled and the spend is shifting to distribution.
Scintillation Research does essentiality, landscape, and infringement research for patent holders.
GET IN TOUCH NOW
OR SCHEDULE A MEETING
